IL17A and Alzheimer disease: Significant advancements have been made in the management of moderate-to-severe AD, including the use of dupilumab, which targets the interleukin (IL)-4 receptor subunit α; tralokinumab, which targets IL-13; secukinumab, which targets IL-17A; and various pan/dual-/selective-Janus kinase (JAK) inhibitors (Bieber, 2022).